Long-term survival benefit of male and multimorbid COVID-19 patients with 5-day remdesivir treatment

BACKGROUND: Treatment of the coronavirus disease (COVID-19) is still challenging due to the lack of evidence-based treatment protocols and continuously changing epidemiological situations and vaccinations. Remdesivir (RDV) is among the few antiviral medications with confirmed efficacy for specific p...

Descripción completa

Detalles Bibliográficos
Autores principales: Polivka, Lorinc, Gajdacsi, Jozsef, Fazekas, Levente, Sebok, Szilvia, Barczi, Eniko, Hidvegi, Edit, Sutto, Zoltan, Dinya, Elek, Maurovich-Horvat, Pal, Szabo, Attila J, Merkely, Bela, Müller, Veronika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Society of Global Health 2022
Materias:
Research Theme 1: COVID-19 Pandemic
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428504/
https://www.ncbi.nlm.nih.gov/pubmed/36040909
http://dx.doi.org/10.7189/jogh.12.05031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428504/
https://www.ncbi.nlm.nih.gov/pubmed/36040909
http://dx.doi.org/10.7189/jogh.12.05031

Ejemplares similares